NIVI welcomes Head of the Project Management Office
The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) is pleased to welcome Mike Whelan as Head of the Project Management Office (PMO).
Mike Whelan is a vaccine specialist focusing on technologies including whole cells, virus like particles, proteins, recombinant viruses and adjuvants. He has worked on both infectious disease and cancer immunotherapy.
He has a scientific background in biochemistry with a PhD in Immunology from The Royal London Hospital Medical School. He has more than 30 years of experience from both academia and industry. He is also an Honorary lecturer at University of Oxford and the Royal Veterinary College.
From China to Denmark
Mike recently moved to Denmark from China, where he worked for Clover Pharmaceuticals. At NIVI he will develop a new Project Management infrastructure, capable of reporting on both early and late-stage projects for both entities in NIVI - NCVI and NVAC - using techniques established over several years at CEPI, Clover and other biotech companies. He will also play a role in Project Leadership for late-stage development projects.
“I am excited to help build the infrastructure for this new initiative. NIVI represents an incredible new opportunity for the development of novel airway-based vaccine immunity,” says Mike Whelan.
NIVI's mission
NIVI's mission is to advance the understanding of systemic and airway immunity and develop vaccines that offer comprehensive protection against respiratory pathogens such as influenza, tuberculosis, and Group A Streptococcus.
NIVI’s Executive Director and CEO, Nicholas Jackson, is thrilled to have Mike Whelan on board:
I have worked together with Mike for many years and I’m sure he will be a great asset on our path towards revolutionizing vaccine development and combating respiratory infections.